Truist Begins Coverage of Carlsmed with a Buy Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Truist Coverage Initiation: Truist has started coverage of Carlsmed with a Buy rating and an $18 price target.
Company Growth Potential: The firm considers Carlsmed to be a high growth company in the spine implant sector, highlighting its predictable alignment and lower revision rates.
Innovative Product Offering: Carlsmed's Aprevo is noted as the first personalized spine implant approved in the U.S., utilizing an AI algorithm to overcome traditional implant challenges.
Analyst Insights: The analyst provided these insights in a research note aimed at informing investors about Carlsmed's potential in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CARL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CARL
Wall Street analysts forecast CARL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.980
Low
18.00
Averages
20.50
High
24.00
Current: 9.980
Low
18.00
Averages
20.50
High
24.00
About CARL
Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights for each surgeon. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Carlsmed Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, representing a 58% year-over-year increase, indicating strong market demand and product acceptance that is expected to drive future revenue growth.
- Operational Efficiency Improvement: By leveraging technology investments, Carlsmed reduced production lead times by over 30% to 6 business days, resulting in 200 basis points of margin expansion, showcasing the company's ongoing improvements in operational efficiency.
- User Base Expansion: The total surgeon user base grew by over 60% year-over-year, indicating increasing acceptance of the aprevo lumbar fusion procedure in the U.S. market, which is expected to further drive market share growth.
- Optimistic Outlook: Carlsmed raised its 2026 revenue guidance to between $72 million and $77 million, reflecting a 48% growth at the midpoint, which demonstrates the company's confidence in new product launches and market expansion.
See More
Carlsmed Reports Q1 Earnings with Revenue of $16.1M
- Earnings Performance: Carlsmed, Inc. reported a Q1 GAAP EPS of -$0.32, indicating challenges in profitability, although revenue reached $16.1 million, reflecting ongoing market demand.
- Revenue Growth Target: The company aims for 2026 revenue between $70 million and $75 million, demonstrating management's confidence in future product launches, particularly in the cervical and bilateral product markets.
- Growth Outlook: Carlsmed anticipates a 44% growth rate moving forward, showcasing strong momentum in the medical device sector, especially post-launch of new products that could attract more customers.
- Historical Financial Data: Despite the current quarter's underperformance, the historical financial data provides investors with context to assess the company's long-term growth potential and market positioning.
See More
Carlsmed (CARL) Q1 2026 Earnings Transcript
See More
Carlsmed Reports Strong Q1 2026 Earnings with 58% Revenue Growth
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, reflecting a 58% year-over-year increase, primarily driven by the expansion of its surgeon user base and increased procedure volumes, indicating a rapidly growing market demand for personalized surgery.
- Surgeon User Base Expansion: The company noted a more than 60% year-over-year increase in surgeon users, highlighting accelerated clinical adoption of personalized surgery procedures, particularly among early-career and post-fellowship surgeons, which further enhances market penetration.
- Improved Production Efficiency: Through technology investments, Carlsmed reduced lead times by over 30%, achieving delivery of surgical kits within six business days post-surgeon approval, and this capital-light, demand-driven model enables rapid scaling while maintaining a focus on patient outcomes.
- Strong Market Outlook: With the recent CMS proposal for 2027, all Aprivile lumbar fusion procedures will receive higher reimbursement, providing greater economic value to hospitals and further driving Carlsmed's growth potential in the spine surgery market.
See More
Carlsmed Reports Q4 Earnings Beat with Strong Revenue Growth Outlook
- Earnings Beat: Carlsmed reported a Q4 GAAP EPS of -$0.32, surpassing expectations by $0.11, indicating positive progress in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $15.2 million, exceeding market expectations by $0.34 million, reflecting strong product demand and an increase in market share.
- Future Outlook: Carlsmed targets revenue between $70 million and $75 million for 2026, with plans to launch cervical and bilateral products, demonstrating confidence in future growth.
- Growth Prospects: The company anticipates a 44% growth outlook, highlighting its competitiveness and ongoing innovation capabilities in the medical device market.
See More
Carlsmed, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Carlsmed reported $15.2 million in revenue for Q4 2025, a 61% increase from $9.4 million in Q4 2024, demonstrating strong expansion potential in the spine surgery market.
- Improved Gross Margins: The gross margin for Q4 reached 76.5%, up from 74.7% in Q4 2024, indicating substantial progress in cost control and operational efficiency.
- New Product Launches: The company announced the launch of the first bilateral posterior aprevo procedure, with a full commercial release planned for the second half of 2026, further enhancing market penetration for personalized spine surgery.
- Optimistic Future Outlook: The CFO projected 2026 revenue between $70 million and $75 million, representing a 44% annual growth rate at the midpoint, reflecting confidence in sustained growth and market demand.
See More
Carlsmed Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, representing a 58% year-over-year increase, indicating strong market demand and product acceptance that is expected to drive future revenue growth.
- Operational Efficiency Improvement: By leveraging technology investments, Carlsmed reduced production lead times by over 30% to 6 business days, resulting in 200 basis points of margin expansion, showcasing the company's ongoing improvements in operational efficiency.
- User Base Expansion: The total surgeon user base grew by over 60% year-over-year, indicating increasing acceptance of the aprevo lumbar fusion procedure in the U.S. market, which is expected to further drive market share growth.
- Optimistic Outlook: Carlsmed raised its 2026 revenue guidance to between $72 million and $77 million, reflecting a 48% growth at the midpoint, which demonstrates the company's confidence in new product launches and market expansion.
See More
Carlsmed Reports Q1 Earnings with Revenue of $16.1M
- Earnings Performance: Carlsmed, Inc. reported a Q1 GAAP EPS of -$0.32, indicating challenges in profitability, although revenue reached $16.1 million, reflecting ongoing market demand.
- Revenue Growth Target: The company aims for 2026 revenue between $70 million and $75 million, demonstrating management's confidence in future product launches, particularly in the cervical and bilateral product markets.
- Growth Outlook: Carlsmed anticipates a 44% growth rate moving forward, showcasing strong momentum in the medical device sector, especially post-launch of new products that could attract more customers.
- Historical Financial Data: Despite the current quarter's underperformance, the historical financial data provides investors with context to assess the company's long-term growth potential and market positioning.
See More
Carlsmed (CARL) Q1 2026 Earnings Transcript
See More
Carlsmed Reports Strong Q1 2026 Earnings with 58% Revenue Growth
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, reflecting a 58% year-over-year increase, primarily driven by the expansion of its surgeon user base and increased procedure volumes, indicating a rapidly growing market demand for personalized surgery.
- Surgeon User Base Expansion: The company noted a more than 60% year-over-year increase in surgeon users, highlighting accelerated clinical adoption of personalized surgery procedures, particularly among early-career and post-fellowship surgeons, which further enhances market penetration.
- Improved Production Efficiency: Through technology investments, Carlsmed reduced lead times by over 30%, achieving delivery of surgical kits within six business days post-surgeon approval, and this capital-light, demand-driven model enables rapid scaling while maintaining a focus on patient outcomes.
- Strong Market Outlook: With the recent CMS proposal for 2027, all Aprivile lumbar fusion procedures will receive higher reimbursement, providing greater economic value to hospitals and further driving Carlsmed's growth potential in the spine surgery market.
See More
Carlsmed Reports Q4 Earnings Beat with Strong Revenue Growth Outlook
- Earnings Beat: Carlsmed reported a Q4 GAAP EPS of -$0.32, surpassing expectations by $0.11, indicating positive progress in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $15.2 million, exceeding market expectations by $0.34 million, reflecting strong product demand and an increase in market share.
- Future Outlook: Carlsmed targets revenue between $70 million and $75 million for 2026, with plans to launch cervical and bilateral products, demonstrating confidence in future growth.
- Growth Prospects: The company anticipates a 44% growth outlook, highlighting its competitiveness and ongoing innovation capabilities in the medical device market.
See More
Carlsmed, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Carlsmed reported $15.2 million in revenue for Q4 2025, a 61% increase from $9.4 million in Q4 2024, demonstrating strong expansion potential in the spine surgery market.
- Improved Gross Margins: The gross margin for Q4 reached 76.5%, up from 74.7% in Q4 2024, indicating substantial progress in cost control and operational efficiency.
- New Product Launches: The company announced the launch of the first bilateral posterior aprevo procedure, with a full commercial release planned for the second half of 2026, further enhancing market penetration for personalized spine surgery.
- Optimistic Future Outlook: The CFO projected 2026 revenue between $70 million and $75 million, representing a 44% annual growth rate at the midpoint, reflecting confidence in sustained growth and market demand.
See More
